NUCLISENS? EASYMAG? MAGNETIC SILICA 384T 280133

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a foreign,health professional,u report with the FDA on 2016-10-06 for NUCLISENS? EASYMAG? MAGNETIC SILICA 384T 280133 manufactured by Biom?rieux Sa.

Event Text Entries

[56941607] An internal biom? Rieux investigation was conducted. Results are as follows: a difference of quantification up to 1 log and sometime more than 1 log was observed , which can be significant on results. As the downstream applications are qualitative and/or quantitative methods, the decrease in performances in downstream application could lead to: a risk of false negative, for qualitative tests. Invalid results, when extracted and amplified internal control is not within specifications. Under-quantification for viral load results for quantitative tests. During the investigation, we confirmed the issue for the following specific customer's applications: impact when using a high sample input volume, from 200 l and up to 1 ml. Impact when double stranded nucleic acid applications with small (<40kbp) and medium genome sizes (to 1200kbp). The root cause has not yet been identified. The investigation is still ongoing internally. Single stranded rna virus applications are not impacted excepted if the rna is extracted without matrix (e. G. In water). No significant impact has been identified for the ivd nuclisens and argene real time pcr kits validated with the easymag and the minimag extraction systems. As stated in the easymag user manual, the use of an internal control is recommended in order to detect any potential nucleic acid extraction issue. The design of the internal control has to be as close as possible to the requested target's design in order to be more efficient. A field safety corrective action (fsca) 3037 has been issued to impacted subsidiaries/distributors to notify affected customers of this issue.
Patient Sequence No: 1, Text Type: N, H10


[56941608] A customer reported a discrepant result when using the nuclisens magnetic silica reagent. The internal control of the eluate did not pass the required customer criteria. When specifically asked, the customer indicated that no death, injury or mistreatment was associated with this issue. The customer did indicate a delay of results of an indeterminate amount of time as a result of needing to rerun the samples. Biomerieux has initiated an investigation into this issue.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number3002769706-2016-00372
MDR Report Key6004413
Report SourceFOREIGN,HEALTH PROFESSIONAL,U
Date Received2016-10-06
Date of Report2016-09-13
Date Mfgr Received2016-09-13
Date Added to Maude2016-10-06
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactMRS. ELLEN WELTMER
Manufacturer Street595 ANGLUM ROAD
Manufacturer CityHAZELWOOD MO 63042
Manufacturer CountryUS
Manufacturer Postal63042
Manufacturer Phone3147317301
Manufacturer G1BIOMERIEUX, SA
Manufacturer StreetCENTRE CHRISTOPHE M 5, RUE DES BERGES
Manufacturer CityGRENOBLE CEDEX 01 38024
Manufacturer CountryFR
Manufacturer Postal Code38024
Single Use3
Remedial ActionNO
Previous Use Code3
Removal Correction NumberFSCA 3037
Event Type3
Type of Report3

Device Details

Brand NameNUCLISENS? EASYMAG? MAGNETIC SILICA 384T
Generic NameNUCLISENS? EASYMAG? MAGNETIC SILICA 384T
Product CodeLDT
Date Received2016-10-06
Catalog Number280133
Lot NumberZ017DA1MS
Device Expiration Date2017-04-28
OperatorHEALTH PROFESSIONAL
Device Availability*
Device Eval'ed by MfgrY
Device Sequence No1
Device Event Key0
ManufacturerBIOM?RIEUX SA
Manufacturer Address5, RUE DES BERGES GRENOBLE CEDEX 01, FR 38024 FR 38024


Patients

Patient NumberTreatmentOutcomeDate
10 2016-10-06

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.